Revance Therapeutics
Signal active
Organization
Contact Information
Overview
Revance Therapeutics is a biopharmaceutical company, engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. Its products include RT001, a physician-applied topical botulinum toxin type A (BoNT-A) for cosmetic, hyperhidrosis, and dermatologic indications. The company was formerly known as Essentia Biosystems, Inc. Revance Therapeutics, Inc. was founded in 2002 and is based in Mountain View, California.
About
Industries
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Founded
2002
Employees
101-250
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Revance Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Therapeutics sector. The company focuses on Biotechnology and has secured $456.8B in funding across 272 round(s). With a team of 101-250 employees, Revance Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series D - Revance Therapeutics, raised $45.0M. Discover more about their projects, partnerships, and impact on our platform.
Employees
George Earl
Vice President of Data-Decisioning | Data Innovation | Data Stewardship | Decision Science
Funding Rounds
Funding rounds
17
Investors
9
Lead Investors
0
Total Funding Amount
$1679.5M
Details
6
Revance Therapeutics has raised a total of $1679.5M in funding over 6 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2004 | Early Stage Venture | 13.0M | ||
| 2009 | Late Stage Venture | 25.6M | ||
| 2013 | Late Stage Venture | 33.0M | ||
| 2011 | Late Stage Venture | 45.0M |
Investors
Revance Therapeutics is funded by 32 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Vivo Capital | - | FUNDING ROUND - Vivo Capital | 45.0M |
| Pac-Link | - | FUNDING ROUND - Pac-Link | 45.0M |
| Revance Therapeutics | - | FUNDING ROUND - Revance Therapeutics | 45.0M |
| Essex Capital Corporation | - | FUNDING ROUND - Essex Capital Corporation | 45.0M |
Recent Activity
There is no recent news or activity for this profile.